Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat + doxorubicin in advanced epithelioid sarcoma
NCT04204941Phase 1Terminated
- Sponsor
- Epizyme, Inc.
- Start
- Dec 2019
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of tazemetostat in epithelioid sarcoma (ES), sponsored by Epizyme, Inc. Primary endpoints: Dose Limiting Toxicities at 21 days and Progression-Free Survival at 2 years. Started Dec 2019; status: terminated.
02
Drugs
tazemetostat
03
Conditions
epithelioid sarcoma (ES)
Beyond the preview
Go deeper on NCT04204941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04204941.